دورية أكاديمية
Bortezomib is effective to treat acute humoral rejection after liver transplantation.
| العنوان: | Bortezomib is effective to treat acute humoral rejection after liver transplantation. |
|---|---|
| المؤلفون: | Lee CF; Chang-Gung Transplantation Institute, Department of Liver and Transplantation Surgery, Chang-Gung Memorial Hospital, Chang-Gung University Medical School, Taoyuan, Taiwan., Eldeen FZ, Chan KM, Wu TH, Soong RS, Wu TJ, Chou HS, Lee WC |
| المصدر: | Transplantation proceedings [Transplant Proc] 2012 Mar; Vol. 44 (2), pp. 529-31. |
| نوع المنشور: | Comparative Study; Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Elsevier Science Inc Country of Publication: United States NLM ID: 0243532 Publication Model: Print Cited Medium: Internet ISSN: 1873-2623 (Electronic) Linking ISSN: 00411345 NLM ISO Abbreviation: Transplant Proc Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: New York, N.Y. : Elsevier Science Inc. Original Publication: New York Stratton. |
| مواضيع طبية MeSH: | Boronic Acids/*therapeutic use , Graft Rejection/*drug therapy , Immunity, Humoral/*drug effects , Immunosuppressive Agents/*therapeutic use , Liver Transplantation/*immunology , Protease Inhibitors/*therapeutic use , Pyrazines/*therapeutic use, Acute Disease ; Aged ; Antibodies, Monoclonal, Murine-Derived/therapeutic use ; Bortezomib ; Drug Therapy, Combination ; Female ; Graft Rejection/enzymology ; Graft Rejection/immunology ; Graft Rejection/mortality ; Graft Survival/drug effects ; Humans ; Immunosuppressive Agents/administration & dosage ; Liver Transplantation/mortality ; Male ; Middle Aged ; Plasmapheresis ; Proteasome Endopeptidase Complex/drug effects ; Proteasome Endopeptidase Complex/metabolism ; Pulse Therapy, Drug ; Retrospective Studies ; Rituximab ; Steroids/administration & dosage ; Taiwan ; Time Factors ; Treatment Outcome |
| مستخلص: | Introduction: Acute humoral rejection (AHR), a rare complication in orthotopic liver transplantation (OLT), responds poorly to conventional therapies. Bortezomib, a proteasome inhibitor, has been shown to be effective in treating plasma cell-derived tumors and acute rejection episodes after renal transplantation. Herein, we have reported our clinical experience with bortezomib as a novel approach to treat AHR after OLT. Methods: We retrospectively analyzed the 247 adult OLTs performed from January 2007 to April 2011. Patients with AHR who were treated with steroid pulses, rituximab (375 mg/m2), and plasmapheresis (PP) were assigned to group A. Group B subjects were prescribed steroid pulses, rituximab, PP, and bortezomib (1.3 mg/m2), after March 2009. Results: Among the 9 patients (3.6%) diagnosed with AHR, all subjects in group A (n=3) died within several days after AHR, whereas 4/6 (66.7%) group B patients were rescued and 3 (50%) survived at a mean follow-up 22.3 months (range, 18-26). Conclusion: Proteasome inhibitor-based therapies provide a more effective strategy to treat AHR after OLT. (Copyright © 2012 Elsevier Inc. All rights reserved.) |
| المشرفين على المادة: | 0 (Antibodies, Monoclonal, Murine-Derived) 0 (Boronic Acids) 0 (Immunosuppressive Agents) 0 (Protease Inhibitors) 0 (Pyrazines) 0 (Steroids) 4F4X42SYQ6 (Rituximab) 69G8BD63PP (Bortezomib) EC 3.4.25.1 (Proteasome Endopeptidase Complex) |
| تواريخ الأحداث: | Date Created: 20120314 Date Completed: 20120801 Latest Revision: 20151119 |
| رمز التحديث: | 20231215 |
| DOI: | 10.1016/j.transproceed.2012.01.051 |
| PMID: | 22410063 |
| قاعدة البيانات: | MEDLINE |
Full Text via ClinicalKey 
Full Text Finder | تدمد: | 1873-2623 |
|---|---|
| DOI: | 10.1016/j.transproceed.2012.01.051 |